NASDAQ:CARA Cara Therapeutics (CARA) Stock Price, News & Analysis $0.30 -0.01 (-3.21%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cara Therapeutics alerts: Email Address About Cara Therapeutics Stock (NASDAQ:CARA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cara Therapeutics alerts:Sign Up Key Stats Today's Range$0.29▼$0.3250-Day Range$0.26▼$0.3852-Week Range$0.24▼$1.87Volume735,438 shsAverage Volume670,435 shsMarket Capitalization$16.51 millionP/E RatioN/ADividend YieldN/APrice Target$2.32Consensus RatingHold Company OverviewCara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Read More… The $15 Stock Powering NVIDIA, TESLA and Microsoft (Ad)The Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Cara Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 87th PercentileCara Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 185th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingCara Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageCara Therapeutics has received no research coverage in the past 90 days.Read more about Cara Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cara Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cara Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cara Therapeutics is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCara Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cara Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.43% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 23.97%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCara Therapeutics does not currently pay a dividend.Dividend GrowthCara Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.39 Percentage of Shares Shorted2.43% of the float of Cara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCara Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cara Therapeutics has recently decreased by 23.97%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.07 News SentimentCara Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cara Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added Cara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cara Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Cara Therapeutics is held by insiders.Percentage Held by Institutions44.66% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cara Therapeutics' insider trading history. Receive CARA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CARA Stock News HeadlinesAnthony Joshua's love life from mother of his son to Cara Delevingne denialSeptember 22 at 3:54 AM | mirror.co.ukAutism campaigner Cara Darmody (14) to hold ‘monster meeting’ outside Leinster HouseSeptember 20 at 11:24 PM | msn.comI accidentally let this slipThe other day, I was having my monthly strategy session with Stephen Ground when I let slip what I think might be the Trade of the Year. To be honest, I wasn’t totally ready to share it yet.September 22, 2024 | ProsperityPub (Ad)Cara Maria says Laurel 'mimicked past abuse' in unseen footage from “The Challenge” season 40 fightSeptember 20 at 11:24 PM | yahoo.comThe Challenge’s Cara Maria Says Laurel ‘Mimicked Past Abuse’ She Suffered During Explosive FightSeptember 20 at 11:24 PM | yahoo.comCara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.comSeptember 19 at 4:49 AM | americanbankingnews.comCara Delevigne's mansion remains in shambles six months on from disastrous fireSeptember 15, 2024 | msn.comLate-Rallying La Cara Takes Pocahontas, Earns Kentucky Oaks PointsSeptember 15, 2024 | msn.comSee More Headlines CARA Stock Analysis - Frequently Asked Questions How have CARA shares performed this year? Cara Therapeutics' stock was trading at $0.7430 on January 1st, 2024. Since then, CARA shares have decreased by 59.4% and is now trading at $0.3020. View the best growth stocks for 2024 here. How were Cara Therapeutics' earnings last quarter? Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Wednesday, August, 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.10. The biopharmaceutical company earned $0.99 million during the quarter, compared to analysts' expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative trailing twelve-month return on equity of 241.31%. Who are Cara Therapeutics' major shareholders? Cara Therapeutics' top institutional shareholders include Disciplined Growth Investors Inc. MN (3.54%), Renaissance Technologies LLC (1.95%) and Acadian Asset Management LLC (0.49%). Insiders that own company stock include Christopher Posner, Frederique PhD Menzaghi, Scott Terrillion, Joana Goncalves, Martin Vogelbaum, Jeffrey L Ives, Ryan D Maynard and Thomas Charles Reilly. View institutional ownership trends. How do I buy shares of Cara Therapeutics? Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX). Company Calendar Last Earnings8/14/2024Today9/22/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CARA CUSIPN/A CIK1346830 Webwww.caratherapeutics.com Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$2.32 High Stock Price Target$5.00 Low Stock Price Target$1.00 Potential Upside/Downside+668.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,510,000.00 Net Margins-1,010.20% Pretax Margin-1,010.20% Return on Equity-241.31% Return on Assets-110.04% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.48 Sales & Book Value Annual Sales$11.00 million Price / Sales1.50 Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book0.29Miscellaneous Outstanding Shares54,676,000Free Float52,981,000Market Cap$16.51 million OptionableOptionable Beta0.70 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:CARA) was last updated on 9/22/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.